Skip to Content

Press Releases

Press Releases

Sep 01 2016
Intec Pharma Reports First Half 2016 Financial Results
Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three and six months ended June 30, 2016. Highlights of the first six months of 2016 and recent weeks
Aug 04 2016
Intec Pharma to Pursue Development of Accordion Pill for Cannabinoid Therapies
Phase 1 clinical trial to begin in first quarter 2017 Intec Pharma Ltd. (Nasdaq:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a new clinical development program for its
Jun 03 2016
Intec Pharma Announces Planned Management Changes
JERUSALEM, June 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Oren Mohar, the company's Chief Financial Officer, has
May 31 2016
Intec Pharma Receives Approval for US$5.2 Million Grant
JERUSALEM, May 31, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, announced today that the Israeli National Authority for
May 16 2016
Intec Pharma to Nominate Dr. John W. Kozarich as Chairman of the Board of Directors
JERUSALEM, May 16, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, announced today that the board of directors of the company
May 03 2016
Intec Pharma Appoints VP of Clinical and Regulatory Affairs
JERUSALEM, May 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the appointment of Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs. "Ms. Strauss-Levy has 15 years of experience in clinical
Apr 06 2016
Intec Pharma Expands Intellectual Property for AP-CDLD with Patent in South Korea
JERUSALEM, Israel, April 6, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the company has been informed that the Korean
Apr 04 2016
Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients
JERUSALEM, April 4, 2016 /PRNewswire/ -- Intec Pharma Ltd.  (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the enrollment in the U.S. of the first patient in its pivotal Phase III clinical trial for its lead product candidate, the Accordion Pill
Mar 17 2016
Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors
JERUSALEM, ISRAEL--(Marketwired - Mar 17, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr.
Mar 14 2016
Intec Pharma Reports 2015 Fourth Quarter and Full-Year Financial Results
JERUSALEM, ISRAEL--(Marketwired - Mar 14, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the year ended
Displaying 61 - 70 of 81